Compugen Ltd.

CGEN

Healthcare Biotechnology

Compugen Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $72.8 million, up 161.1% from fiscal 2024.

Revenue
+107.0%
EPS
+12.5%
Free cash flow
−155.4%

Quarter to June 2026, against a year earlier

1.96 0.04 +2.08%
Market cap
$185.7M
P/E
5.2×
Fwd P/E
n/m
Dividend yield
—
F-score
7/9
ROIC
0.00%
Net debt / EBITDA
−4.7×
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
7 — — —

+8 more TTM periods

ROE
47.85% 0.00% 42.00% 0.00%
ROA
23.86% 26.68% 26.03% (24.95%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
32.75% 30.08% 28.02% (39.79%)
Average Days of Receivables
20.27 11.75 11.95 149.74
Free Cash Flow per Share
0.42 0.00 1.09 0.00
Free Cash Flow
40.04 — 101.69 —
Other line items

Show all line items

Columns are period end dates